thymopoietin pentapeptide
Peptideexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002050)
Timeline
Indications
Mechanism of action
LAP2A activator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O- Mol. weight
- 679.78 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL156025 ↗
Also known as
- orf-15244
- orf-15244
- thymopentin
- thymopentin
- thymopentin
- thymopentin
- thymopentin
- thymopentin
- thymopentin
- thymopentin
- thymopoietin 32-36
- thymopoietin 32-36
- thymopoietin 32-36
- thymopoietin pentapeptide
- tp-5
- tp-5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00460681 | Phase 3 | Feb 1, 2007 | Fudan University |
| NCT00002050 | N/A | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002051 | N/A | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002066 | N/A | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002049 | N/A | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002289 | N/A | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002332 | Phase 2 | Nov 2, 1999 | Cedars-Sinai Medical Center |
| NCT00002109 | Phase 3 | Nov 2, 1999 | Cedars-Sinai Medical Center |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Academic/Hospital | 7 | 7 | 3 | 1999 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1